New products of interest to our readers
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
March 22nd 2023Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
Improving built environments could help address adolescent obesity
March 21st 2023Built environments, but not social and economic environments, were negatively associated with BMI and overweight or obesity status, with a stronger association among adolescents with longer exposure to their built environment.
2 Clarke Drive
Cranbury, NJ 08512